| p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells. | |
| | |
MedLine Citation:
|
PMID: 20042273 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Imatinib is a Bcr-Abl inhibitor used as first-line therapy of chronic myeloid leukemia (CML). p21(Cip1), initially described as a cell cycle inhibitor, also protects from apoptosis in some models. We describe that imatinib down-regulates p21(Cip1) expression in CML cells. Using K562 cells with inducible p21 expression and transient transfections we found that p21 confers partial resistance to imatinib-induced apoptosis. This protection is not related to the G2-arrest provoked by p21, a decrease in the imatinib activity against Bcr-Abl or a cytoplasmic localization of p21. The results suggest an involvement of p21(Cip1) in the response to imatinib in CML. |
| | |
Authors:
|
Nuria Ferrandiz; Juan M Caraballo; Marta Albajar; M Teresa Gomez-Casares; Carmen E Lopez-Jorge; Rosa Blanco; M Dolores Delgado; Javier Leon |
Related Documents
:
|
11159753 - Role of tp53 in repair of n-(deoxyguanosin-8-yl)-4-aminobiphenyl adducts in human trans... 15177183 - Immortalized mouse cell lines that lack a functional rev3 gene are hypersensitive to uv... 6344133 - Differential inactivation analysis of diploid yeast exposed to radiation of various let... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-12-29 |
Journal Detail:
|
Title: Cancer letters Volume: 292 ISSN: 1872-7980 ISO Abbreviation: Cancer Lett. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-04-13 Completed Date: 2010-04-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600053 Medline TA: Cancer Lett Country: Ireland |
Other Details:
|
Languages: eng Pagination: 133-9 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Departamento de Biolog?a Molecular, Facultad de Medicina, Instituto de Biomedicina y Biotecnolog?a de Cantabria, Universidad de Cantabria-CSIC-IDICAN, Santander, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Apoptosis
/
drug effects Cell Line, Tumor Cyclin-Dependent Kinase Inhibitor p21 / metabolism* Drug Resistance, Neoplasm* G2 Phase / drug effects Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*, metabolism Piperazines / antagonists & inhibitors*, therapeutic use* Pyrimidines / antagonists & inhibitors*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/CDKN1A protein, human; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Detection of chronic lymphocytic leukemia cell surface markers using surface enhanced Raman scatteri...
Next Document: ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.